NeoGenomics Laboratories | Date: 2016-08-17
A method for predicting resistance to BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) enhances the sensitivity of Sanger sequencing and NGS by using wild-type blocking of genes that are relevant for detecting resistance to ibrutinib. Further enhancement of sensitivity can be achieved by using cell-free DNA.
News Article | November 22, 2016
According to Stratistics MRC, the Global Liquid Biopsy market is expected to grow from $0.63 billion in 2015 to reach $2.93 billion by 2022 with a CAGR of 24.6%. Increasing research & developments and clinical trials for diagnostics, and technological developments are some of the factors driving the market growth. Moreover, growing prevalence of cancer, increasing awareness about liquid biopsy are the factors fostering the market growth. On the other hand, higher costs and complex regulations are restraining the market growth. Access the complete report at: The circulating tumor cells leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. By cancer type, lung cancer segment is expected to witness high growth rate during the forecast period. North America emerged as the major revenue generating region in the global market due to innovative technological developments, and increasing incidence of cancer rates in the Canada and U.S. Asia Pacific and Latin America are expected to witness high growth rate during the forecast period. Some of the key players in global liquid biopsy market include Adaptive Biotechnologies, Biocept, Inc., Bio-Rad Laboratories Inc., Guardant Health Inc., Fraunhofer-Gesellschaft, F. Hoffmann-La Roche AG, Epic Sciences, Cynvenio, Illumina Inc., Qiagen, Personal Genome Diagnostics, NeoGenomics Laboratories, Myriad Genetics, Trovagene Inc., RainDance Technologies, MDX Health SA, and Janssen Diagnostics, LLC. Request for a sample at: http://www.strategymrc.com/report/liquid-biopsy-market Sample Types Covered: • Urine • Blood • Others o CSF o Plasma o Saliva Cancer Types Covered: • Gastrointestinal Cancer • Colorectal Cancer • Breast Cancer • Leukemia • Prostate Cancer • Lung Cancer • Liver Cancer • Other Cancers o Ovarian Cancer o Melanoma o Bladder Cancer Circulating Biomarkers Covered: • Extracellular Vesicles (EVs) • Circulating Tumor DNA (ctDNA) • Exosomes • Circulating Tumor Cells (CTCs) • Other Biomarkers o Circulating RNA and Protein Products and Services Covered: • Services and Software • Reagents • Instruments End Users Covered: • Hospital and Physician Laboratories • Diagnostic Centers • Academic & Research Centers • Others End User o Small Molecular Laboratories o Public Health Laboratories o Pathology Laboratories Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements
NeoGenomics Laboratories | Date: 2015-12-10
An automated method and system are provided for receiving an input of flow cytometry data and analyzing the data using a hierarchical arrangement of analytical elements, each of which utilizes a support vector machine to automatically classify the data into different subpopulations to recognize a pattern within the data. The pattern may be used to generate a diagnostic prediction for a patient or to identify patterns within samples collected from multiple subjects.
NeoGenomics Laboratories | Date: 2013-12-03
The present invention relates to a method for screening, predicting or prognosing esophageal adenocarcinoma/high grade dysplasia in a subject.
NeoGenomics Laboratories | Date: 2015-11-11
Methods are provided for treating, managing, diagnosing and monitoring myelodysplastic syndrome and other hematologic malignancies. These methods comprise the next generation sequencing analysis conducted on cell-free DNA from peripheral blood plasma or serum.
NeoGenomics Laboratories | Date: 2015-11-11
Compositions and fragment length analysis methods are provided for detecting CALR mutations and determining tumor load in patients with myeloproliferative neoplasms.
NeoGenomics Laboratories | Date: 2016-07-01
A method for increasing sensitivity for detecting minority mutations in MYD88 uses a locked nucleic acid oligo to block amplification of wild-type DNA in DNA isolated from patient FFPE tissue, bone marrow aspirate or peripheral blood samples during PCR while still allowing sequencing and visualization of the PCR product. Further improvement to the sensitivity may be achieved by using a uracil DNA-glycosylase treatment to remove sequence artifacts commonly found in formalin-fixed, paraffin-embedded tissue.
NeoGenomics Laboratories | Date: 2014-03-13
The present disclosure provides methods of detecting and determining the aggressiveness of prostate cancer. These methods can be used to determine whether or not a patient needs a biopsy as well as guide treatment selection.
NeoGenomics Laboratories | Date: 2013-09-11
An automated reader for reading fluorescence in-situ hybridization signals includes one or more computer processors for receiving a digitized FISH image and executing the steps of converting colors within the image to a hue value, separately for each color extracting quantitative values to detect the presence of signals corresponding to spots and applying a plurality of algorithms to extract features from the signals to determine cell shapes and segment cells within the FISH image. After recombining the signals, the extracted features for the colors learning machines are used to classify the spots according to the color and separate merged signals of classified spots that are in close proximity to each other within the image. The classified spots are counted to determine relative frequency of colors and a report is generated providing the number of classified spots of each color.
NeoGenomics Laboratories | Date: 2016-04-20
A method for detecting a low-occurrence mutation in isolated DNA adds a blocking probe to reagents during amplification of the isolated DNA. The blocking probe is an oligonucleotide complementary to wild-type DNA corresponding to the sample. The blocking probe spans a site of a suspected mutation within a region of interest in the isolated DNA. After amplification, fragments of the amplified DNA is sequenced using next generating sequencing and an output is generated to display the sequenced fragments. In some embodiments, the blocking probe is locked nucleic acid (LNA).